References
- Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1–22
- Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
- Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83
- Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. Clin Endocrinol Metab 2004;89:770–5
- Stepan H, Geide A, Faber R. Soluble fms-like tyrosine kinase 1. N Engl J Med 2004;351:2241–2
- Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. Clin Endocrinol Metab 2005;90:4895–903
- Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38
- Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008;453:1117–21
- Svedas E, Nisell H, Vanwijk MJ, et al. Endothelial dysfunction in uterine circulation in preeclampsia: can estrogens improve it? Am J Obstet Gynecol 2002;187:1608–16
- Chafetz I, Kuhnreich I, Sammar M, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007;197:35.e1–7
- Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2008;115:1465–72
- Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945–52
- Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010;63:601–10
- Fukui A, Funamizu A, Yokota M, et al. Uterine and circulating natural killer cells and their roles in women with recurrent pregnancy loss, implantation failure and preeclampsia. J Reprod Immunol 2011;90:105–10
- Scherjon S, Lashley L, van der Hoorn ML, Claas F. Fetus specific T cell modulation during fertilization, implantation and pregnancy. Placenta 2011;32:S291–7
- Dekker G, Robillard PY, Roberts C. The etiology of preeclampsia: the role of the father. J Reprod Immunol 2011;89:126–32
- Nevers T, Kalkunte S, Sharma S. Uterine regulatory T cells, IL-10 and hypertension. Am J Reprod Immunol 2011;66:88–92
- Kalkunte S, Nevers T, Norris WE, Sharma S. Vascular IL-10: a protective role in preeclampsia. J Reprod Immunol 2011;88:165–9
- Ahn H, Park J, Gilman-Sachs A, Kwak-Kim J. Immunologic characteristics of preeclampsia, a comprehensive review. Am J Reprod Immunol 2011;65:377–94
- Foidart JM, Schaaps JP, Chantraine F, et al. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia – a step forward but not the definitive answer. J Reprod Immunol 2009;82:106–11
- Hertig A, Liere P. New markers in preeclampsia. Clin Chim Acta 2010;411:1591–5
- Davison JM. Renal haemodynamics and volume homeostasis in pregnancy. Scand J Clin Lab Invest Suppl 1984;169:15–27
- Ueland K, Metcalfe J. Circulatory changes in pregnancy. Clin Obstet Gynecol 1975;18:41–50
- Clark SL, Cotton DB, Lee W, et al. Central hemodynamic assessment of normal term pregnancy. Am J Obstet Gynecol 1989;161:1439–42